01:25 , Nov 28, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on GDF1, MYH6 and FLT4 could help predict the risk of subtypes of congenital heart disease. Whole-exome sequencing of 2,871 congenital heart disease patients identified associations between severe disease in the Ashkenazi...
07:00 , Jul 12, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Myocardial infarction (MI) Myosin heavy chain 6 cardiac muscle-a (MYH6) Mouse studies suggest blocking autoimmune activity against cardiac myosin could help reduce damage following...
08:00 , Nov 7, 2011 |  BioCentury  |  Strategy

Servicing CV

While some pharmas have concluded cardiovascular disease is well served by generics and are exiting the space, Servier believes it can grow its CV business by in-licensing novel, first-in-class programs. Last month, Servier agreed to...
07:00 , Apr 7, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiomyopathy Myosin heavy chain 6 cardiac muscle-a (MYH6) Studies in mice and in human samples suggest that inducing tolerance to MYH6 could help...
07:00 , Jun 16, 2008 |  BioCentury  |  Emerging Company Profile

Miragen: The heart of miRNA

Miragen: The heart of miRNA...